Skip to main content

RETRACTION article

Front. Oncol., 07 December 2023
Sec. Pharmacology of Anti-Cancer Drugs
Volume 13 - 2023 | https://doi.org/10.3389/fonc.2023.1337635

Retraction: Emodin interferes with AKT1-mediated DNA damage and decreases resistance of breast cancer cells to doxorubicin

This article is a retraction of:

  1. RETRACTED: Emodin Interferes With AKT1-Mediated DNA Damage and Decreases Resistance of Breast Cancer Cells to Doxorubicin

    1. Read original article
Frontiers Editorial Office* Frontiers Editorial Office*

    A Retraction of the Original Research Article
    Emodin interferes with AKT1-mediated DNA damage and decreases resistance of breast cancer cells to doxorubicin

    by Li B, Zhao X, Zhang L and Cheng W (2021) Front. Oncol. 10:588533. doi: 10.3389/fonc.2020.588533

    The journal retracts the February 2021 article cited above.

    Following publication, the authors contacted the Editorial Office to request the retraction of the cited article, stating concerns regarding the use of an incorrect dataset in the published article. It was confirmed by the authors when they tried to repeat their experiments unsuccessfully. The findings and conclusions reported in the article are no longer supported by the data. An investigation was conducted in in accordance with Frontiers’ policies that confirmed this; therefore, the article is retracted.

    This retraction was approved by the Chief Editors of Frontiers in Oncology and the Chief Executive Editor of Frontiers. The authors agree to this retraction.

    Citation: Frontiers Editorial Office (2023) Retraction: Emodin interferes with AKT1-mediated DNA damage and decreases resistance of breast cancer cells to doxorubicin. Front. Oncol. 13:1337635. doi: 10.3389/fonc.2023.1337635

    Received: 13 November 2023; Accepted: 13 November 2023;
    Published: 07 December 2023.

    Approved by:

    Giuseppe Giaccone, Vice President Global Development, United States

    Copyright © 2023 Frontiers Editorial Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    *Correspondence: Frontiers Editorial Office, research.integrity@frontiersin.org

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.